Adeno-Associated Virus Vector Delivery of Microrna-29 to Treat Muscular Dystrophy

Abstract

The invention provides for recombinant AAV vectors comprising a polynucleotide sequence comprising the guide strand of miR-29c and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from muscular dystrophy.

1 . (canceled) 
     
     
         2 . The recombinant AAV vector comprising
 a) the nucleotide sequences of SEQ ID NO: 3 and SEQ ID NO: 4,   b) the nucleotide sequence of SEQ ID NO: 2,   c) the nucleotide sequence of SEQ ID NO: 1 or   d) the nucleotide sequence of SEQ ID NO: 12.   
     
     
         3 . The recombinant AAV vector of  claim 2  wherein the vector is a the serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV11, AAV12 or AAV13. 
     
     
         4 . The recombinant AAV vector  claim 2  wherein the polynucleotide sequence is operably linked to a muscle-specific control element. 
     
     
         5 . The recombinant AAV vector of  claim 4  wherein the muscle-specific control element is cytomegalovirus (CMV) promoter, human skeletal actin gene element, cardiac actin gene element, myocyte-specific enhancer binding factor mef, muscle creatine kinase (MCK), truncated MCK (tMCK), myosin heavy chain (MHC), MHCK7, C5-12, murine creatine kinase enhancer element, skeletal fast-twitch troponin c gene element, slow-twitch cardiac troponin c gene element, the slow-twitch troponin i gene element, hypoxia-inducible nuclear factors, steroid-inducible element or glucocorticoid response element (gre). 
     
     
         6 . The recombinant AAV vector of  claim 4  wherein the muscle-specific control element comprises the nucleotide sequence of SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 13. 
     
     
         7 . A composition comprising the recombinant AAV vector of  claim 2 . 
     
     
         8 . A method of treating muscular dystrophy comprising administering a therapeutically effective amount of the recombinant AAV vector of  claim 2 . 
     
     
         9 . A method of reducing or preventing fibrosis in a subject suffering from muscular dystrophy comprising administering a therapeutically effective amount of the recombinant AAV vector of  claim 2 . 
     
     
         10 . A method of preventing fibrosis in a patient suffering from muscular dystrophy comprising administering a therapeutically effective amount of the recombinant AAV vector of  claim 2 . 
     
     
         11 . A method of increasing muscular force or muscle mass in a subject suffering from muscular dystrophy comprising administering a therapeutically effective amount of the recombinant AAV vector of  claim 2 . 
     
     
         12 . The method of  claim 8  wherein the muscular dystrophy is Duchenne muscular dystrophy or Limb Girdle muscular dystrophy. 
     
     
         13 . The method of  claim 8  wherein the recombinant AAV vector or the composition is administered by intramuscular injection. 
     
     
         14 . The method of  claim 8  wherein the recombinant AAV vector or the composition is administered systemically. 
     
     
         15 . The method of  claim 14 , where the recombinant AAV vector or the composition is parenterally administered by injection, infusion or implantation. 
     
     
         16 . The method of  claim 8 , wherein the recombinant AAV vector of composition is administered before fibrosis is observed in the subject or before muscle force is reduced in the subject or before muscle mass is reduced in the subject. 
     
     
         17 - 31 . (canceled) 
     
     
         32 . A method of producing a mature miR-29 polynucleotide sequence comprising infecting a host cell with a recombinant AAV vector of  claim 2  and expressing a mature miR-29 polynucleotide in the host cell.